• Exchange: EN Brussels
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

ThromboGenics NV

+ Add to Watchlist

THR:BB

7.9900 EUR 0.0100 0.13%

As of 11:37:19 ET on 09/19/2014.

Snapshot for ThromboGenics NV (THR)

Open: 7.9910 Day's Range: 7.8500 - 7.9990 Volume: 89,305
Previous Close: 8.0000 52wk Range: 7.8500 - 24.0000 1-Yr Rtn: -64.14%

Stock Chart for THR

No chart data available.
  • THR:BB 7.9900
  • 1D
  • 1M
  • 1Y
8.0000
Interactive THR Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for THR

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. BEL20 -
Earnings Per Share (EUR) (ttm) -1.4500
Est. EPS (EUR) (12/2014) -1.3370
Est. PEG Ratio -
Market Cap (M EUR) 288.39
Shares Outstanding (M) 36.09
30 Day Average Volume 92,645
Price/Book (mrq) 1.2276
Price/Sale (ttm) 16.7423
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/17/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for THR

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for THR

ThromboGenics NV is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company is focused on developing medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system.

Gustaaf Van Reet "Staf"ChairmanPatrik De HaesCEO/Executive Director
Luc PhilipsInterim CFOKoen KasChief Scientific Officer
More Company Profile & Key Executives for THR

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil